Search Results - "Kumar, Shaji"

THE AUTHORS REPLY.

Authors: Rajkumar, S. Vincent Kumar, Shaji

Source: New England Journal of Medicine. 1/1/2026, Vol. 394 Issue 1, p101-102. 2p.

Risk stratification and early intervention in smoldering multiple myeloma.

Authors: Sra, Manraj Singh Kumar, Shaji

Source: Leukemia & Lymphoma. Jan2026, Vol. 67 Issue 1, p55-63. 9p.

Cardiac Amyloidosis AI‐ECG Model is Useful in Predicting Outcomes in Multiple Myeloma Patients Without Amyloidosis Undergoing Autologous Stem Cell Transplant.

Authors: Tan, Melinda S. Y. Gertz, Morie A. Muchtar, Eli et al.

Source: Advances in Hematology. 3/8/2026, Vol. 2026, p1-7. 7p.

Global patterns of amyloid typing: results of a survey by the International Society of Amyloidosis (ISA).

Authors: Naiki, Hironobu Johnson, Mona Walters, Kaylee et al.

Source: Amyloid. Jun2025, Vol. 32 Issue 2, p139-144. 6p.

Sustained Improvement in Health‐Related Quality of Life in Transplant‐Ineligible Newly Diagnosed Multiple Myeloma Treated With Daratumumab, Lenalidomide, and Dexamethasone: MAIA Final Analysis of Patient‐Reported Outcomes.

Authors: Perrot, Aurore Facon, Thierry Plesner, Torben et al.

Source: European Journal of Haematology. May2025, Vol. 114 Issue 5, p883-889. 7p.

Risk-adapted treatment for multiple myeloma: assessing the current potential and a roadmap for the future.

Authors: Zanwar, Saurabh Kumar, Shaji

Source: Leukemia & Lymphoma. Apr2025, Vol. 66 Issue 4, p573-583. 11p.

Whole-Exome Sequencing-Based Linkage Analysis of Multiple Myeloma (MM) and Monoclonal Gammopathy of Undetermined Significance (MGUS) Pedigrees.

Authors: Clay-Gilmour, Alyssa I. Camp, Nicola J. Wei, Xiaomu et al.

Source: Cancers. Nov2025, Vol. 17 Issue 22, p3611. 15p.

Impact of cytogenetic abnormalities on treatment outcomes in patients with amyloid light-chain amyloidosis: subanalyses from the ANDROMEDA study.

Authors: Kumar, Shaji Dispenzieri, Angela Bhutani, Divaya et al.

Source: Amyloid. Sep2023, Vol. 30 Issue 3, p268-278. 11p.

Proteomic determinants of renal organ response in light-chain amyloidosis.

Authors: Rees, Matthew J. Muchtar, Eli Atallah-Yunes, Suheil-Albert et al.

Source: Amyloid. Jun2025, Vol. 32 Issue 2, p200-202. 3p.

Hepatic involvement in light chain amyloidosis: analysis of 130 patients and predictors of hepatic response and survival.

Authors: Rees, Matthew J. Toumeh, Nadia Dispenzieri, Angela et al.

Source: Amyloid. Sep2025, Vol. 32 Issue 3, p267-275. 9p.

Author index.

Source: Quality of Life Research. Oct2021 Supplement 1, Vol. 30 Issue 1, p179-196. 18p.

Subjects: Chinese martial arts

Whole tissue proteomic analyses of cardiac ATTR and AL unveil mechanisms of tissue damage.

Authors: Netzel, Brian C. Charlesworth, M. Cristine Johnson, Kenneth L. et al.

Source: Amyloid. Mar2025, Vol. 32 Issue 1, p72-80. 9p.

BCMA-directed therapy, new treatments in the myeloma toolbox, and how to use them.

Authors: Rees, Matthew James Kumar, Shaji

Source: Leukemia & Lymphoma. Mar2024, Vol. 65 Issue 3, p287-300. 14p.

Characterization and prognostic implication of delayed complete response in AL amyloidosis.

Authors: Muchtar, Eli Gertz, Morie A. Kumar, Shaji K. et al.

Source: European Journal of Haematology. Mar2021, Vol. 106 Issue 3, p354-361. 8p.

Oral Therapies for Multiple Myeloma.

Authors: Singhal, Sachi Kumar, Shaji

Source: touchREVIEWS in Oncology & Haematology. 2022, Vol. 18 Issue 2, p139-151. 13p.

Mass spectrometry-based lipidomics identifies select triacylglycerol species as differentially abundant in the bone marrow microenvironment of patients with multiple myeloma compared to monoclonal gammopathy of unknown significance.

Authors: Chawla, Yogesh Anderson, Emilie I. Jevremovic, Dragan et al.

Source: Metabolomics. Jun2025, Vol. 21 Issue 3, p1-15. 15p.

Differences in the proteome within extracellular vesicles between premalignant and malignant plasma cell disorders.

Authors: Vanderboom, Patrick M. Chawla, Yogesh Dasari, Surendra et al.

Source: European Journal of Haematology. Sep2024, Vol. 113 Issue 3, p351-356. 6p.

Front‐line treatment patterns in multiple myeloma: An analysis of U.S.‐based electronic health records from 2011 to 2019.

Authors: Kumar, Shaji Williamson, Mellissa Ogbu, Uzor et al.

Source: Cancer Medicine. Sep2021, Vol. 10 Issue 17, p5866-5877. 12p.

PI3K/AKT/mTOR pathway in multiple myeloma: from basic biology to clinical promise.

Authors: Ramakrishnan, Vijay Kumar, Shaji

Source: Leukemia & Lymphoma. Nov2018, Vol. 59 Issue 11, p2524-2534. 11p.

Central nervous system involvement (Bing-Neel Syndrome) in patients with Waldenström macroglobulinemia.

Authors: Zanwar, Saurabh Abeykoon, Jithma P. Ansell, Stephen M. et al.

Source: Leukemia & Lymphoma. Jul/Aug2023, Vol. 64 Issue 8, p1490-1493. 4p.